Clear Search

Showing 1 result for “Scholtes RA”.

October 2022

Mechanisms underlying the blood pressure-lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial

Diabetes Obes Metab. 2022; online ahead of print DOI: 10.1111/dom.14864

This prespecified analysis of the RECOLAR study investigated the effects of the sodium-glucose co-transporter-2 inhibitor (SGLT2i), empagliflozin, the angiotensin receptor blocker (ARB), losartan, and their combination on blood-pressure lowering, while studying the mechanisms potentially involved.

more…